Company
Nuwellis
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
2
510(k), De Novo and PMA
Device trials
8
As lead sponsor, any status
Adverse event reports
5
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
NUWE
Nasdaq · Nuwellis, Inc.
Public float
$4.6M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$8.3M
Fiscal year ending Dec 31, 2025
Net income
-$17.5M
Fiscal year ending Dec 31, 2025
R&D spending
$2.7M
Fiscal year ending Dec 31, 2025
Cash
$8.3M
As of Sep 30, 2026
Long-term debt
Not reported
Shares outstanding
0.5M
As of Nov 10, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | $2.9M | $4.0M | – | – |
| 2024 | – | $2.4M | – | – |
| 2023 | $2.1M | – | – | – |
| 2022 | $9.4M | – | – | – |
| 2021 | $27.9M | – | – | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2024 | Options or warrants | $3.8M | $3.8M | 9 | Rule 506(b)Agent: Ladenburg Thalmann & Co. Inc.Commissions $383K | Form D ↗Nov 20, 2024 |
| Aug 26, 2024 | Options or warrants | $0 | Open-ended | 6 | Rule 506(b)Agent: Ladenburg Thalmann & Co. Inc.Commissions $71K | Form D ↗Sep 4, 2024 |
| Jul 25, 2024 | Options or warrants | $0 | Open-ended | 7 | Rule 506(b)Agent: Roth Capital Partners, LLCCommissions $139K | Form D ↗Aug 2, 2024 |
1 more funding rounds with a free account
Company details
From the company's latest Form D.
- Legal name
- Nuwellis, Inc.
- Headquarters
- Eden Prairie, Minnesota
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- $5,000,001 - $25,000,000
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1506492 ↗
Executives, directors and promoters
As listed on the latest Form D.
9 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
K252226 · Decided Aug 13, 2025 · 28 days after receipt
Device type: Catheter, Hemodialysis, Non-Implanted, Ultrafiltration, For Peripheral Use (NQJ) · GI, Urology & Nephrology
K233515 · Decided Dec 26, 2023 · 55 days after receipt
Device type: Catheter, Hemodialysis, Non-Implanted, Ultrafiltration, For Peripheral Use (NQJ) · GI, Urology & Nephrology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Ultrafiltration Versus IV Diuretics in Worsening Heart FailurePivotal-lookingTerminated
NCT05318105 · 167 participants · Start Jun 28, 2022 · Primary completion Oct 6, 2025
Device: Aquadex Smartflow® System · For: Heart Failure (for Example, Fluid Overload); Heart Failure; Fluid Overload
Sites: Tucson, Arizona; Long Beach, California; San Diego, California · 15 sites in all
NCT04241718 · 6 participants · Start Dec 19, 2019 · Primary completion Dec 27, 2022
Device: Aquadex FlexFlow System and BVA-100 · For: Acute Decompensated Heart Failure; Fluid Overload
Sites: Naperville, Illinois
NCT04644731 · 97 participants · Start Apr 9, 2021 · Primary completion Sep 13, 2023
Device: Aquadex™ System · For: Fluid Overload
Sites: Birmingham, Alabama; Palo Alto, California; Hollywood, Florida · 7 sites in all
5 more trials with a free account
Reports received
5
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
0.0% of reports
Injury reports
4
80% of reports
Death reports
1
20% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 1 | 2 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 1 | 0 | 0 |
| Feb 26 | 0 | 1 | 0 | 0 |
| Mar 26 | 0 | 1 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 1 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 1 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0831-2025 · Started Dec 11, 2024 · Posted by FDA Jan 16, 2025
Reason given: The AquaFlexFlow UF 500 Plus extracorporeal blood circuit used with the Aquadex SmartFlow and FlexFlow Systems may indicate "Ultrafiltrate Weight Mismatch" or Excessive Weight Mismatch Alarms while in use. If not addressed, this failure could result in excess fluid removal from a patient leading to Acute Volume...
Cause as FDA categorized it: Under Investigation by firm · Device type: Dialyzer, High Permeability With Or Without Sealed Dialysate System (KDI)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.